This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
All You Need to Know About Roche Holding (RHHBY) Rating Upgrade to Strong Buy
by Zacks Equity Research
Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
Best Momentum Stocks to Buy for August 23rd
by Zacks Equity Research
APELY, RHHBY, and SBSI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 23, 2024.
New Strong Buy Stocks for August 23rd
by Zacks Equity Research
RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.
Best Value Stocks to Buy for August 23rd
by Zacks Equity Research
RHHBY, SBSI, and FCCO made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 23, 2024.
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
by Zacks Equity Research
Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
by Zacks Equity Research
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
by Zacks Equity Research
Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.
Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024. Stock rises in after-hours trading.
The Market's Excessive Recession Fears
by Sheraz Mian
We comment on the ongoing market sell-off, in addition to featuring new research reports on Johnson & Johnson (JNJ), T-Mobile (TMUS) and Marsh & McLennan (MMC) and others.
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
by Zacks Equity Research
Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
by Zacks Equity Research
Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
by Zacks Equity Research
Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India.
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Affimed's (AFMD) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline candidates being developed for various cancer indications.
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
by Ahan Chakraborty
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
by Zacks Equity Research
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
by Zacks Equity Research
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
Pfizer (PFE) Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline
by Zacks Equity Research
Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.
The Zacks Analyst Blog Highlights Broadcom, Roche, Micron Technology and Moving iMage Technologies
by Zacks Equity Research
Broadcom, Roche, Micron Technology and Moving iMage Technologies are part of the Zacks top Analyst Blog.
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.
Top Analyst Reports for Broadcom, Roche & Micron Technology
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Roche Holding AG (RHHBY) and Micron Technology, Inc. (MU), as well a micro-cap stock Moving iMage Technologies, Inc. (MITQ).
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
by Sundeep Ganoria
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.